Eight patients with chronic inflammatory demyelinating polyneurophy, five of whom had an associated paraproteinaemia, were treated with cyclosporin in a pilot, uncontrolled study for periods up to three and a halfyears after failing to respond adequately to cortiscosteroid and azathioprine therapy and plasmapheresis. Three patients had an excellent response, two with complete remission. In other cases it was possible to reduce the corticosteroid therapy and frequency of plasmapheresis. There were no serious complications of the treatment.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disease of the peripheral nerves with a relapsing and remitting, or progressive course. ' This patient with arelapse of CIDP that had failed to respond to intensive treatment with corticosteroids and plasma exchange improved considerably after starting CsA. No further relapses have occurred during the six month period of treatment.
Discussion
Three patients had CIDP and five others had a chronic demyelinating neuropathy with similar clinical and pathological features, but an associated benign paraproteinaemia. In each case there was a severe disability that had not responded to treatment with corticosteroids, azathioprine and plasmapheresis. They were all having maintenance plasmapheresis at the time of starting CsA therapy. In all cases some benefit was derived from CsA; three patients (cases 1, 2 and 8) had an excellent response and two of these (cases 1 and 2) went into complete remission. Cases 1 and 2 were treated for periods of three and a half and two and a half years respectively and have remained in remission for more than one year since therapy has stopped. In most cases it was possible to reduce the corticosteroid dose or stop the drug altogether, and to reduce the frequency of plasmapheresis or discontinue it entirely. In two cases (cases 1 and 5) there had been a recurrence of symptoms when the CsA dosage was reduced within the first six months of treatnent, an observation that supports the therapeutic value of the CsA treatment. There were no significant changes in the nerve conduction studies in any of the patients over the observation periods.
There were no serious side effects in any patient and none had persistent impairment of renal function.
CsA is thought to act partly as an immunosuppressive agent by inhibiting lymphokine release (including gamma interferon and interleukin 2) and target cell responsiveness to lymphokine, rather than by affecting cytotoxic killing mechanisms. 
